Search

Displaying results 4631 - 4640 of 6198 in total
  1. Drug

    VE303

    go.drugbank.com/drugs/DB17794
    Investigational

    VE303 is under clinical development by Vedanta Biosciences.

  2. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  3. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.

  4. Drug

    4-O-Demethylpenclomedine

    go.drugbank.com/drugs/DB06331
    Experimental

  5. Drug

    FS-1502

    go.drugbank.com/drugs/DB19287
    Investigational

    FS-1502 is an antibody-drug conjugate consisting of an anti-HER2 antibody, linker, and Monomethylauristatin F.

  6. Drug

    PAC-113

    go.drugbank.com/drugs/DB05756
    Investigational

    PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.

  7. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  8. Drug

    Porphobilinogen

    go.drugbank.com/drugs/DB02272
    Experimental

    It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.

  9. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.

  10. Drug

    TT-232

    go.drugbank.com/drugs/DB12088
    Investigational

    Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).